- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Marisa C. Maleck
News 20 results
In the News · Source: The Washington Post
In the News · Source: Law360
July 7, 2021
Marisa Maleck is profiled as a Law360 Rising Star
Recognition
June 1, 2021
Four King & Spalding Lawyers Named Law360 Rising Stars
In the News · Source: Washington DC citybizlist, The Daily Docket, The American Lawyer and Bloomberg Law
January 8, 2021
FDA and Life Sciences partner Marisa Maleck rejoins the firm's Government Matters practice group in Washington, D.C.
Events 5 results
Webinar
April 27, 2021
What to Expect From the DOJ in the Biden Administration
Webinar
February 23, 2021
Key Food and Beverage Issues: Challenges and Opportunities in 2021
Webinar
January 30, 2020
Congress 2020: The Year Ahead
Webinar
January 28, 2020
Key Food and Beverage Issues: What to Expect in 2020
Insights 8 results
Client Alert
August 27, 2021
FDA Rejects Bids To Market CBD-Based Dietary Supplements
Newsletter
August 25, 2021
International Food Law Gazette – August 2021
Client Alert
February 2, 2021
USDA Issues Final Rule to Establish Domestic Hemp Production Program and Approve State and Tribal Oversight Plans
Article · Source: Washington Legal Foundation
November 2, 2018
Utah Court Should Find Medical Devices Merit Exception to Strict Product Liability